Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Aug 2022 Status changed from active, no longer recruiting to discontinued, according to the results published in the Journal of Allergy and Clinical Immunology.
27 Aug 2022 Primary endpoint (Percent Change of Total Eczema Area and Severity Index (EASI) Score) has not been met, according to Results published in the Journal of Allergy and Clinical Immunology.
27 Aug 2022 Results assessing the efficacy, safety, and pharmacokinetics of astegolimab in patients with atopic dermatitis published in the Journal of Allergy and Clinical Immunology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com